Original Article
Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae
N Engl J Med 2006; 354:1455-1463April 6, 2006
- Abstract
Background
Five of seven serotypes in the pneumococcal conjugate vaccine, introduced for infants in the United States in 2000, are responsible for most penicillin-resistant infections. We examined the effect of this vaccine on invasive disease caused by resistant strains.
Methods
We used laboratory-based data from Active Bacterial Core surveillance to measure disease caused by antibiotic-nonsusceptible pneumococci from 1996 through 2004. Cases of invasive disease, defined as disease caused by pneumococci isolated from a normally sterile site, were identified in eight surveillance areas. Isolates underwent serotyping and susceptibility testing.
Results
Rates of invasive disease caused by penicillin-nonsusceptible strains and strains not susceptible to multiple antibiotics peaked in 1999 and decreased by 2004, from 6.3 to 2.7 cases per 100,000 (a decline of 57 percent; 95 percent confidence interval, 55 to 58 percent) and from 4.1 to 1.7 cases per 100,000 (a decline of 59 percent; 95 percent confidence interval, 58 to 60 percent), respectively. Among children under two years of age, disease caused by penicillin-nonsusceptible strains decreased from 70.3 to 13.1 cases per 100,000 (a decline of 81 percent; 95 percent confidence interval, 80 to 82 percent). Among persons 65 years of age or older, disease caused by penicillin-nonsusceptible strains decreased from 16.4 to 8.4 cases per 100,000 (a decline of 49 percent). Rates of resistant disease caused by vaccine serotypes fell 87 percent. An increase was seen in disease caused by serotype 19A, a serotype not included in the vaccine (from 2.0 to 8.3 per 100,000 among children under two years of age).
Conclusions
The rate of antibiotic-resistant invasive pneumococcal infections decreased in young children and older persons after the introduction of the conjugate vaccine. There was an increase in infections caused by serotypes not included in the vaccine.
Media in This Article
Figure 1
Annual Incidence of Invasive Disease Caused by Penicillin-Susceptible and Penicillin-Nonsusceptible Pneumococci among Children under Two Years of Age, 1996 to 2004.Figure 2
Annual Incidence of Invasive Disease Caused by Penicillin-Nonsusceptible Pneumococci in Persons Two Years of Age or Older, 1996 to 2004.Article Activity
- Article
Antibiotic-resistant pneumococci complicate treatment decisions, cause treatment failures, and increase the costs of medical care. Worldwide, most antibiotic-resistant infections are caused by five of the seven serotypes in the 7-valent pneumococcal conjugate vaccine (6B, 9V, 14, 19F, and 23F).1 In 1998, 24 percent of invasive pneumococcal isolates in the United States were nonsusceptible to penicillin, and these five serotypes comprised 78 percent of such strains.2 Modeling predicted that in the absence of a pneumococcal conjugate vaccine, the proportion of pneumococcal strains that were nonsusceptible to both penicillin and erythromycin could reach 41 percent by 2004.3 Because of the association between serotype and resistance, the conjugate vaccine would be expected to reduce the incidence of disease caused by resistant strains, even though the vaccine is designed to induce antibodies against certain capsular types.
A pneumococcal conjugate vaccine was licensed for use in young children in the United States in 2000. The vaccine is recommended for all children under two years of age and for children two to four years of age who have certain chronic illnesses or other high-risk conditions.4 Data from 20015 and from a single site in 20026 indicated that there had been a large decrease in invasive disease, including infections caused by resistant strains. Whether vaccine use would induce the emergence of serotypes that were typically not resistant as clinically significant causes of resistant infections was unknown. In addition, the possibility that use of a vaccine that targets only 7 of 90 pneumococcal serotypes would lead to an increase in disease by nonvaccine types (so-called replacement disease) was a concern. We used population-based data from Active Bacterial Core surveillance, part of the Emerging Infections Program of the Centers for Disease Control and Prevention (CDC), to evaluate further the effect of the conjugate pneumococcal vaccine on invasive disease caused by antibiotic-resistant strains in the United States.
Methods
Active Bacterial Core surveillance is an active, population-based system that has been described previously (www.cdc.gov/abcs).2 We included cases of invasive pneumococcal disease identified from January 1, 1996, through December 31, 2004, in eight surveillance areas: the Atlanta metropolitan area (eight counties); Portland, Oregon (three counties); San Francisco County, California; Minneapolis and St. Paul (seven counties); the Baltimore metropolitan area (six counties); the state of Connecticut; and parts of Tennessee (four counties). Seven counties comprising the Rochester, New York, metropolitan area were added in 1998. The surveillance methods for detecting cases of invasive pneumococcal disease did not change during the study period. The population under surveillance for this analysis ranged from 14.3 million to 16.9 million, including nearly 500,000 children under two years of age.
Active Bacterial Core surveillance methods defined a case of invasive disease as an illness in which pneumococcus was isolated from a normally sterile site, such as blood, cerebrospinal fluid, or pleural fluid. Isolates underwent susceptibility testing by broth microdilution at the CDC, the Minnesota Department of Health, or the University of Texas Health Science Center at San Antonio. Antibiotic susceptibility was defined according to break points for minimal inhibitory concentrations as determined in 2004 by the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards).7 Isolates with intermediate or high-level resistance were defined as nonsusceptible. Isolates were considered nonsusceptible to multiple antibiotics if they were nonsusceptible to at least three of the following: penicillin, erythromycin, trimethoprim–sulfamethoxazole, tetracycline, chloramphenicol, clindamycin, rifampin, and levofloxacin.
Serotyping was performed at the CDC or the Minnesota Department of Health by the Quellung reaction. The 7-valent conjugate vaccine serotypes included types 4, 6B, 9V, 14, 18C, 19F, and 23F. Other serotypes in these serogroups, including 6A, 9A, 9L, 9 N, 18A, 18B, 18F, 19A, 19B, 19C, 23A, and 23B, were regarded as vaccine-related. All others were nonvaccine types.
Rates of invasive pneumococcal disease, expressed as the number of cases per 100,000 population, were calculated for the surveillance areas with the use of estimates from the U.S. Census Bureau for each respective year, followed by adjustment for race and age according to the U.S. population. Projected numbers of cases in the United States were determined by multiplying the adjusted rate by the U.S. population. Estimated numbers of cases for 2004 were calculated on the basis of the 2003 population. Because isolates were not available for all cases, rates of antibiotic-nonsusceptible disease were computed by multiplying the percentage of cases that were nonsusceptible by the total rate of disease calculated with all cases. Likewise, we calculated serotype-specific rates according to the assumption that the distribution of serotypes among cases without serotype data was the same as that among cases with serotype data. Changes in the rates of antibiotic-nonsusceptible disease were calculated for the comparison between 1999 — the year before the vaccine was introduced — and 2004. Two-sided P values of less than 0.05 were considered to indicate statistical significance and were not adjusted for multiple testing.
SAS (version 9.1, SAS Institute) and StatXact programs were used for data analysis. We used multivariable logistic-regression modeling to assess factors associated with invasive disease caused by penicillin-nonsusceptible pneumococci in 2004. We assessed collinearity and interactions among variables in the final model.
Results
All Ages
We identified 28,336 cases from 1996 through 2004; isolates were available for 24,825 (87.6 percent). For 96.4 percent of the cases, isolates were available from blood; for 3.8 percent, from cerebrospinal fluid; for 1.5 percent, from pleural fluid; and for 1.0 percent, from other sources (for some cases, isolates were available from more than one source). All isolates were serotyped and tested for antibiotic susceptibility.
Overall rates of invasive pneumococcal disease ranged from 23.7 to 25.1 cases per 100,000 persons between 1996 and 1999; the number of cases per 100,000 persons decreased to 20.9 in 2000, 16.9 in 2001, 14.0 in 2002, 14.0 in 2003, and 12.6 in 2004. The incidence of penicillin-nonsusceptible disease increased from 5.4 cases per 100,000 in 1996 to a peak of 6.3 per 100,000 in 1999 (P<0.04). Comparing 1999 and 2004 data, we found that the overall rate of penicillin-nonsusceptible disease decreased from 6.3 to 2.7 per 100,000 (a decline of 57 percent; 95 percent confidence interval, 55 to 58 percent) (Table 1Table 1
Incidence of Invasive Pneumococcal Disease Caused by Penicillin-Nonsusceptible Strains in 1999 and 2004, According to Serotype.). Similar decreases were found for erythromycin-nonsusceptible disease (from 4.7 to 2.3 per 100,000, a decline of 51 percent [95 percent confidence interval, 50 to 53 percent]) and for disease caused by strains with reduced susceptibility to multiple antibiotics (from 4.1 to 1.7 per 100,000, a decline of 59 percent [95 percent confidence interval, 58 to 60 percent]). Rates of penicillin-nonsusceptible disease due to vaccine serotypes fell from 5.0 to 0.7 per 100,000 (a decline of 87 percent; 95 percent confidence interval, 86 to 88 percent) (Table 1). Rates of disease caused by vaccine-related strains increased by 54 percent (from 1.0 to 1.6 per 100,000); this change reflected a decrease (by 22 percent) in the rate of disease due to serotype 6A and a large increase (by 238 percent) in the rate of disease due to serotype 19A. The rate of penicillin-nonsusceptible disease due to nonvaccine serotypes increased from 0.2 per 100,000 in 1999 to 0.5 per 100,000 in 2004.The decrease in the rate of penicillin-nonsusceptible disease was largest in Georgia (a decrease of 68 percent, from 11.1 per 100,000 in 1999 to 3.6 per 100,000 in 2004) and smallest in New York (a decrease of 11 percent, from 3.3 to 2.9 per 100,000). The rate of penicillin-nonsusceptible disease decreased by 65 percent (from 11.7 to 4.1 per 100,000) in Tennessee, by 60 percent (from 5.5 to 2.2 per 100,000) in Minnesota, by 57 percent (from 3.7 to 1.6 per 100,000) in Oregon, by 53 percent (from 3.8 to 1.8 per 100,000) in California, by 53 percent (from 5.8 to 2.7 per 100,000) in Maryland, and by 42 percent (from 4.9 to 2.9 per 100,000) in Connecticut. The change in rate was significant at all sites except New York.
The proportion of isolates that were penicillin-nonsusceptible increased from 21.6 percent in 1996 to 25.8 percent in 1999 and 25.9 percent in 2000 and fell to 21.6 percent in 2004 (P<0.001 for the comparison between 1999 and 2004). The proportion of erythromycin-nonsusceptible isolates ranged from 10.7 percent in 1996 to 19.4 percent in 1999 and 20.6 percent in 2000; the proportion of isolates that were erythromycin-nonsusceptible did not change significantly after the introduction of the vaccine and was 18.1 percent in 2004 (P=0.23 for the comparison with 1999 rates). When data from 1999 and 2004 were compared with respect to other drugs, significant decreases were seen in the proportion of isolates that were nonsusceptible to trimethoprim–sulfamethoxazole, cefuroxime, meropenem, or clindamycin or to three or more drug classes, but there were no significant changes in the proportion of isolates that were nonsusceptible to cefotaxime, tetracycline, or levofloxacin. The proportion of isolates that were nonsusceptible to any tested antibiotic was 37.7 percent in 1999 and 33.6 percent in 2004 (P=0.002). Most individual serotypes were not less resistant in 2004 than in 1999 (Table 2Table 2
Total Number of Strains from Cases of Invasive Pneumococcal Disease and Percentage That Were Penicillin-Nonsusceptible (PNS) in 1999 and 2004, According to Serotype and Age.). Among the vaccine serotypes, only serotype 23F was significantly less often resistant in 2004 than in 1999; vaccine-related serotype 19A was resistant more often.Rates of Disease According to Age
Children under Five Years of Age
The rates of penicillin-nonsusceptible invasive disease among children under five years of age ranged from 25.9 to 33.8 per 100,000 between 1996 and 1999, before the introduction of the conjugate vaccine, and fell to 7.5 per 100,000 in 2004. Rates of resistant infections were highest among children under two years of age, the target age for use of the conjugate vaccine. In this age group, the rate of invasive disease caused by penicillin-nonsusceptible pneumococci decreased by 81 percent (95 percent confidence interval, 80 to 82 percent), from a peak of 70.3 per 100,000 in 1999 to 13.1 per 100,000 in 2004 (Figure 1Figure 1
Annual Incidence of Invasive Disease Caused by Penicillin-Susceptible and Penicillin-Nonsusceptible Pneumococci among Children under Two Years of Age, 1996 to 2004.). The rate of invasive disease due to erythromycin-nonsusceptible strains decreased by 80 percent (95 percent confidence interval, 78 to 81 percent), from 58.6 to 12.0 per 100,000, and the rate of disease due to strains with reduced susceptibility to both penicillin and erythromycin decreased by 83 percent (95 percent confidence interval, 82 to 85 percent), from 51.5 to 8.6 per 100,000. Among children two to four years of age, the rate of penicillin-nonsusceptible disease decreased by 60 percent (95 percent confidence interval, 56 to 65 percent), from 9.4 to 3.7 per 100,000 (Figure 2Figure 2Annual Incidence of Invasive Disease Caused by Penicillin-Nonsusceptible Pneumococci in Persons Two Years of Age or Older, 1996 to 2004.). The rate of disease caused by strains nonsusceptible to multiple antibiotics decreased by 84 percent (95 percent confidence interval, 82 to 85 percent), from 53.8 to 8.8 per 100,000, among children under two years of age, and by 64 percent (95 percent confidence interval, 58 to 68 percent), from 6.2 to 2.3 per 100,000, among children two to four years of age.Among children under two years of age, almost all infections caused by penicillin-nonsusceptible strains were due to vaccine and vaccine-related serotypes, both before and after introduction of the vaccine (Table 1). In this age group, a large reduction in disease caused by vaccine serotypes was accompanied by an increase in non–vaccine-serotype disease. The rate of disease caused by nonsusceptible 19A, a vaccine-related serotype, increased markedly (from 2.0 to 8.3 per 100,000). Among children two to four years of age, the rate of penicillin-nonsusceptible disease caused by vaccine serotypes decreased by 98 percent (95 percent confidence interval, 96 to 99 percent), from 6.9 per 100,000 in 1999 to 0.2 per 100,000 in 2004.
Among children under two years of age, the proportion of cases due to nonsusceptible strains fell after vaccine licensure but then increased in 2004, such that no change overall was seen between 1999 and 2004 for most of the antibiotics tested (Figure 3AFigure 3
Percentage of Pneumococcal Isolates That Were Nonsusceptible to Various Antibiotics from Children under Two Years of Age (Panel A) and Adults 65 Years of Age or Older (Panel B) with Invasive Disease, 1999 to 2004.). In this age group, the proportion of isolates with intermediate resistance to penicillin was 12.8 percent in 1999, 10.7 percent in 2000, 14.0 percent in 2001, 7.4 percent in 2002, 10.8 percent in 2003, and 18.4 percent in 2004; the prevalence of high-level resistance was 26.2 percent, 26.4 percent, 21.3 percent, 13.2 percent, 13.2 percent, and 19.1 percent, respectively. The proportion of isolates nonsusceptible to one or more antibiotics did not differ significantly between 1999 and 2004 either among children under two years of age (52.5 percent and 51.7 percent, respectively; P=0.87) or among children two to four years of age (43.5 percent and 40.0 percent, respectively; P=0.61). Individual serotypes were as likely to be resistant in 2004 as they were in 1999 (Table 2). In 2004, a single serotype, 19A, accounted for 35 percent (51 of 147) of all penicillin-nonsusceptible strains among children under two years of age, as compared with only 2 percent (13 of 711) in 1999.Persons Five Years of Age or Older
The rates of disease caused by penicillin-nonsusceptible strains also decreased among persons five years of age or older — a group that would not have received the conjugate vaccine (Figure 2). The rates of penicillin-nonsusceptible disease were highest among adults 65 years of age or older; in this group, the rate of penicillin-nonsusceptible disease decreased from 16.4 per 100,000 in 1999 to 8.4 per 100,000 in 2004 — a reduction of 49 percent (95 percent confidence interval, 46 to 51 percent) (Table 1). The rate of penicillin-nonsusceptible disease decreased by 41 percent (95 percent confidence interval, 32 to 48 percent), from 0.9 to 0.5 per 100,000, among persons 5 to 19 years of age; by 51 percent (95 percent confidence interval, 46 to 55 percent), from 1.6 to 0.8 per 100,000, among persons 20 to 39 years of age; and by 36 percent (95 percent confidence interval, 33 to 40 percent), from 4.3 to 2.7 per 100,000, among those 40 to 64 years of age.
The proportion of isolates that were nonsusceptible to penicillin fell among adults 65 years of age or older (Figure 3B). A similar pattern of decrease in the proportion of penicillin resistance was seen in other age groups. For erythromycin, the proportion of isolates that were resistant decreased from 13.8 percent in 1999 to 11.4 percent in 2004 among persons 5 to 19 years of age (P=0.63), but there were no significant changes among those 20 to 39 years of age (proportion of erythromycin-resistant isolates, 11.9 percent in 1999 and 12.6 percent in 2004), among those 40 to 64 years of age (14.7 percent and 16.9 percent, respectively), or among those 65 years of age or older (18.6 percent and 18.5 percent, respectively).
The decrease in penicillin-nonsusceptible disease among older children and adults was due to a drop in disease caused by vaccine serotypes. Among adults 65 years of age or older, the rate of penicillin-nonsusceptible disease caused by vaccine serotypes decreased by 79 percent (Table 1). Conversely, a small but significant increase was seen in the rate of penicillin-nonsusceptible disease caused by nonvaccine serotypes and vaccine-related serotype 19A in this group.
Factors Associated with Resistant Infections
The proportion of cases of disease caused by penicillin-nonsusceptible strains differed somewhat among locations in 2004, ranging from 29.5 percent in Tennessee, 28.5 percent in Georgia, and 25.0 percent New York to 15.5 percent in Oregon and 9.4 percent in California (P<0.001 for the comparison among the surveillance areas). After adjustment according to site, children under 5 years of age and adults 65 years of age or older were more likely to be infected with penicillin-nonsusceptible strains than were those 18 to 64 years of age (odds ratio, 2.5 [95 percent confidence interval, 1.8 to 3.6] and 1.2 [95 percent confidence interval, 1.0 to 1.6], respectively). No significant associations were seen between nonsusceptibility to penicillin and race, hospitalization status, and diagnosis or outcome.
Overall Changes in the Burden of Disease
The estimated annual number of cases of invasive pneumococcal disease in the United States decreased from 66,100 in 1999 to 36,600 in 2004. Cases due to strains that were nonsusceptible to at least one of the antibiotics tested decreased by 51 percent, from 25,000 in 1999 to 12,300 in 2004. The size of the decrease in resistant cases among children under five years of age (from an estimated 8800 cases in 1999 to 2000 cases in 2004) was similar to that among persons five years of age or older (from 16,300 to 10,300). The number of deaths due to invasive pneumococcal disease decreased from 7200 in 1999 to 4700 in 2004; deaths caused by strains resistant to at least one antibiotic decreased from 2500 to 1600 annually.
Discussion
The incidence of antibiotic-resistant invasive disease declined substantially after the introduction of the pneumococcal conjugate vaccine into the routine childhood immunization program. Among children under two years of age, the rate of penicillin-nonsusceptible invasive disease fell 81 percent; rates among children two to four years of age were 60 percent lower in 2004 than at baseline in 1999. These results complement earlier reports of a decline in resistant disease among children in other parts of the United States after the introduction of the conjugate vaccine.6,8,9 Because the vaccine was licensed in 2000, nearly all the children up through the age of four years in 2004 would have had the opportunity to receive the conjugate vaccine as an infant or toddler. According to estimates of U.S. vaccine coverage, only 73 percent of children 19 to 35 months old in 2004 had received at least three of the recommended four doses of conjugate pneumococcal vaccine.10 Therefore, the changes we report occurred in a setting in which many children were not fully vaccinated.
In addition to reductions in the rates among young children, reductions in the rates of invasive disease caused by resistant strains were documented among older children and adults, who would not have received the conjugate vaccine. With all age groups considered together, the estimated number of cases caused by strains with reduced susceptibility to penicillin or multiple antibiotics fell by half after the introduction of the conjugate vaccine. Studies of adults have shown that exposure to children can increase the risk of colonization11 and invasive disease.12 Conjugate pneumococcal vaccines have been shown to reduce the risk of carriage and transmission of vaccine-type strains among vaccinees and their household members.13 The change that we observed in the rate of resistant disease among adults was due to a reduction in disease caused by vaccine serotypes — a finding suggesting that the vaccine interrupts the transmission of resistant pneumococci from children to adults. We found no reduction in the incidence of resistant disease caused by serotypes included in the 23-valent polysaccharide vaccine but not in the 7-valent conjugate vaccine (data not shown); therefore, it appears that the decline in invasive antibiotic-resistant disease among adults was not linked to an increase in the use of the polysaccharide vaccine. Polysaccharide-vaccine coverage among adults 65 years of age or older increased from 54 percent in 1999 to 64 percent in 2003.14,15
We found an increase in resistant disease caused by nonvaccine types (so-called replacement disease), but the magnitude of this effect was relatively small. Most resistant infections from serotypes not in the vaccine were caused by serotypes 6A and 19A. A drop in the rate of disease caused by serotype 6A and a concurrent increase in the rate of disease due to serotype 19A suggest, as previously reported, that the 6B vaccine component provides cross-protection16-18 against serotype 6A disease but that the 19F component does not protect against 19A disease.16,19 The increase in resistant disease caused by serotype 19A is a concern. Serotype 19A is often resistant and is a common cause of respiratory tract infections.20,21 It is difficult to predict whether the increase in resistant serotype 19A or other serotypes not covered by the vaccine will continue. Nevertheless, this replacement disease has the potential to reduce the overall benefit of the vaccine against resistant infections.
Our analysis indicates that groups at particular risk for resistant infections have changed since the introduction of the conjugate vaccine. Before its introduction, young children had the highest risk of infections due to antibiotic-resistant strains2; we noted similar rates of antibiotic-nonsusceptible disease among children under 2 years of age and adults 65 years of age or older. The multivariable model indicated that among those with infections, white children were no longer more likely than black children to have a resistant infection — a finding that represents a change from the results of analysis with a similar model based on 1998 data.2 We continued to note geographic differences in the prevalence of resistance after the introduction of the vaccine, with resistance being most common among isolates from states in the southeastern United States.
Policymakers considering routine use of the pneumococcal conjugate vaccine in settings in which resistance is prevalent should recognize this reduction in resistant infections as an added benefit to vaccine use. Because many pneumococci remain resistant, the changes we report are not likely to change recommendations regarding the empirical treatment of pneumonia, otitis media, and meningitis; those recommendations are designed to cover the possibility of infection due to resistant pneumococci.22-25 Nonetheless, the drop in the rate of disease due to resistant strains may mean that fewer complications and treatment failures due to resistance will occur.
Presented in part at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003 (abstract G-2045).
Supported by the Emerging Infections Program of the CDC and by the Antimicrobial Resistance Working Group.
No potential conflict of interest relevant to this article was reported.
We are indebted to all personnel in the Active Bacterial Core Surveillance of the Emerging Infections Program sites — especially Wendy Baughman, Georgia Department of Health; Pam Daily, California Department of Health Services; Peggy Pass, Maryland Department of Health and Mental Hygiene; Nancy Barrett, Connecticut Department of Health; Paul Cieslak and Karen Stefonek, Department of Human Services, Office of Disease Prevention and Epidemiology, Oregon; Shelly Zansky and Brenda Barnes, New York State Department of Health; David Stephens, Emory University, Department of Medicine, Atlanta; Catherine Lexau, Rich Danila, Billie Juni, and Anita Glennen, Minnesota Department of Health; Tami Hilger Skoff, Tamar Pilishvili, Sandi McCoy, Chris Van Beneden, Carolyn Wright, Delois Jackson, Ruth Franklin, and Andrea Hertz, Respiratory Diseases Branch, CDC, Atlanta; and Sharon A. Crawford, M. Leticia McElmeel, Letitia Fulcher, and Christa Trippy, University of Texas Science Center at San Antonio — as well as to personnel from the hospitals and laboratories participating in the Active Bacterial Core Surveillance for their contributions to this project; to Matt Moore for his helpful comments on the manuscript; and to Katie Benton and Angela Roberson for providing assistance in data analysis.
Source Information
From the Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta (M.H.K., R.R.F., E.R.Z., A.S., C.G.W.); the Minnesota Department of Health, Minneapolis (R.L., J.B.); Vanderbilt University School of Medicine (W.S.) and the Tennessee Department of Health (A.S.C.) — both in Nashville; the Connecticut Department of Public Health, Hartford (J.H.); the School of Public Health, University of California, Berkeley (A.R.); the Emerging Infections Programs, Oregon Department of Human Services, Health Division, Portland (A.R.T.); Johns Hopkins University Bloomberg School of Public Health, Baltimore (L.H.H.); the Monroe County Department of Health and the University of Rochester — both in Rochester, N.Y. (N.M.B.); Emory University School of Medicine and the Veterans Affairs Medical Center — both in Atlanta (M.M.F.); and the University of Texas Health Science Center, San Antonio (J.H.J.).
Address reprint requests to Dr. Whitney at CDC Mailstop C-23, 1600 Clifton Rd. NE, Atlanta, GA 30333, or at cwhitney@cdc.gov.
- References
References
1
Schrag SJ ,Beall B ,Dowell SF . Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 2000;13:588-601
CrossRef | Web of Science | Medline2
Whitney CG ,Farley MM ,Hadler J , et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-1924
Full Text | Web of Science | Medline3
McCormick AW ,Whitney CG ,Farley MM , et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003;9:424-430
CrossRef | Web of Science | Medline4
Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49:1-35
Medline5
Whitney CG ,Farley MM ,Hadler J , et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-1746
Full Text | Web of Science | Medline6
Talbot TR ,Poehling KA ,Hartert TV , et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004;39:641-648
CrossRef | Web of Science | Medline7
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: fourteenth informational supplement. Wayne, Pa.: NCCLS, 2004. (NCCLS document M100-S14.)
8
Kaplan SL ,Mason EO Jr ,Wald ER , et al. Decrease of invasive pneumococcal infections among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443-449
CrossRef | Web of Science | Medline9
Pelton SI ,Loughlin AM ,Marchant CD . Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J 2004;23:1015-1022
CrossRef | Web of Science | Medline10
National, state, and urban area vaccination coverage among children aged 19-35 months -- United States, 2004. MMWR Morb Mortal Wkly Rep 2005;54:717-721
Medline11
Hendley JO ,Sande MA ,Stewart PM ,Gwaltney MJ Jr . Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis 1975;132:55-61
CrossRef | Web of Science | Medline12
Nuorti JP ,Butler JC ,Farley MM , et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000;342:681-689
Full Text | Web of Science | Medline13
Givon-Lavi N ,Fraser D ,Dagan R . Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003;22:524-532
CrossRef | Web of Science | Medline14
Influenza and pneumococcal vaccination levels among persons aged > or = 65 years -- United States, 1999. MMWR Morb Mortal Wkly Rep 2001;50:532-537
Medline15
Influenza and pneumococcal vaccination coverage among persons aged > or = 65 years and persons aged 18-64 years with diabetes or asthma -- United States, 2003. MMWR Morb Mortal Wkly Rep 2004;53:1007-1012[Erratum, MMWR Morb Mortal Wkly Rep 2005;54:935.]
Medline16
Eskola J ,Kilpi T ,Palmu A , et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-409
Full Text | Web of Science | Medline17
Black S ,Shinefield H ,Fireman B , et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195
CrossRef | Web of Science | Medline18
Klugman KP ,Madhi SA ,Huebner RE , et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003;349:1341-1348
Full Text | Web of Science | Medline19
Kilpi T ,Ahman H ,Jokinen J , et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003;37:1155-1164
CrossRef | Web of Science | Medline20
Hausdorff WP ,Yothers G ,Dagan R , et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 2002;21:1008-1016
CrossRef | Web of Science | Medline21
Dagan R ,Givon-Lavi N ,Zamir O ,Fraser D . Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003;22:532-540
CrossRef | Web of Science | Medline22
Pneumococcal infections. In: Pickering LK, Baker CJ, Overturf GD, et al., eds. 2003 Red book: report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, Ill.: American Academy of Pediatrics, 2003:490-500.
23
Tunkel AR ,Hartman BJ ,Kaplan SL , et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-1284
CrossRef | Web of Science | Medline24
Subcommittee on Management of Acute Otitis Media
CrossRef | Web of Science | Medline25
Mandell LA ,Bartlett JG ,Dowell SF , et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-1433
CrossRef | Web of Science | Medline
- Citing Articles (224)
Citing Articles
1
Pierre Olivier Lang, Richard Aspinall. (2012) Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?. Expert Review of Vaccines 11:2, 167-176
CrossRef2
Ann Lismond, Sylviane Carbonnelle, Jan Verhaegen, Patricia Schatt, Annelies De Bel, Paul Jordens, Frédérique Jacobs, Anne Dediste, Frank Verschuren, Te-Din Huang, Paul M. Tulkens, Youri Glupczynski, Françoise Van Bambeke. (2012) Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. International Journal of Antimicrobial Agents
CrossRef3
Koh Cheng Thoon, Chia Yin Chong, Nancy Wen Sim Tee. (2012) Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010. International Journal of Infectious Diseases
CrossRef4
L. M. Hampton, M. M. Farley, W. Schaffner, A. Thomas, A. Reingold, L. H. Harrison, R. Lynfield, N. M. Bennett, S. Petit, K. Gershman, J. Baumbach, B. Beall, J. Jorgensen, A. Glennen, E. R. Zell, M. Moore. (2011) Prevention of Antibiotic-Nonsusceptible Streptococcus pneumoniae With Conjugate Vaccines. Journal of Infectious Diseases
CrossRef5
E. Ríos Dueñas, I. Rodríguez-Avial, J. J. Picazo. (2011) In vitro activity of ceftobiprole and seven other antimicrobial agents against invasive Streptococcus pneumoniae isolates in Spain. European Journal of Clinical Microbiology & Infectious Diseases 30:12, 1621-1625
CrossRef6
Wei Dong, Xiaojun Chen, Ke Liu, Haitao Chen, Zhiliang Sun. (2011) Serum antibody coupled with the construction of gentamicin sulfate for the Escherichia coli targeted drug. Research in Veterinary Science 91:3, e136-e143
CrossRef7
, N. Grall, O. Hurmic, M. Nakib, M. Longo, C. Poyart, M.-C. Ploy, E. Varon, J. Raymond. (2011) Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. European Journal of Clinical Microbiology & Infectious Diseases 30:12, 1511-1519
CrossRef8
Chiara Azzari, Maria Moriondo, Martina Cortimiglia, Claudia Valleriani, Clementina Canessa, Giuseppe Indolfi, Silvia Ricci, Maurizio de Martino, Massimo Resti. (2011) Potential serotype coverage of three pneumococcal conjugate vaccines against invasive pneumococcal infection in Italian children. Vaccine
CrossRef9
Robert W Frenck, Sylvia Yeh. (2011) The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opinion on Biological Therapy1-15
CrossRef10
M. Woodhead, F. Blasi, S. Ewig, J. Garau, G. Huchon, M. Ieven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, R. Read, T. J. M. Verheij, . (2011) Guidelines for the management of adult lower respiratory tract infections - Summary. Clinical Microbiology and Infection 17, 1-24
CrossRef11
M. Woodhead, F. Blasi, S. Ewig, J. Garau, G. Huchon, M. Ieven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, R. Read, T. J. M. Verheij, . (2011) Guidelines for the management of adult lower respiratory tract infections - Full version. Clinical Microbiology and Infection 17, E1-E59
CrossRef12
Elizabeth Rightmier, Vanessa Stevens, Jack Brown. (2011) Streptococcus pneumoniae Vaccination in Older Adults. The American Journal of Geriatric Pharmacotherapy
CrossRef13
K. P. Klugman. (2011) Contribution of vaccines to our understanding of pneumococcal disease. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2790-2798
CrossRef14
L. A. Hicks, Y.-W. Chien, T. H. Taylor, M. Haber, K. P. Klugman, . (2011) Outpatient Antibiotic Prescribing and Nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clinical Infectious Diseases 53:7, 631-639
CrossRef15
J. S. Bradley, C. L. Byington, S. S. Shah, B. Alverson, E. R. Carter, C. Harrison, S. L. Kaplan, S. E. Mace, G. H. McCracken, M. R. Moore, S. D. St Peter, J. A. Stockwell, J. T. Swanson. (2011) The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clinical Infectious Diseases 53:7, e25-e76
CrossRef16
E. Grimprel, F. Laudat, S. Patterson, S.A. Baker, M.S. Sidhu, W.C. Gruber, E.A. Emini, D.A. Scott. (2011) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine
CrossRef17
Gail L. Rodgers, Keith P. Klugman. (2011) The future of pneumococcal disease prevention. Vaccine 29, C43-C48
CrossRef18
Rob J.L. Willems, William P. Hanage, Debra E. Bessen, Edward J. Feil. (2011) Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiology Reviews 35:5, 872-900
CrossRef19
Lakshmi Khandke, Cindy Yang, Ksenia Krylova, Kathrin U. Jansen, Abbas Rashidbaigi. (2011) Preservative of choice for Prev(e)nar 13™ in a multi-dose formulation. Vaccine 29:41, 7144-7153
CrossRef20
Adriano Arguedas, Carolina Soley, Arturo Abdelnour. (2011) Prevenar experience. Vaccine 29, C26-C34
CrossRef21
Angela Gentile, Virginia Bazán. (2011) Prevention of pneumococcal disease through vaccination. Vaccine 29, C15-C25
CrossRef22
Vicenç Falcó, Ana Sánchez, Albert Pahissa, Jordi Rello. (2011) Emerging drugs for pneumococcal pneumonia. Expert Opinion on Emerging Drugs 16:3, 459-477
CrossRef23
D. KARLSSON. (2011) Probabilistic network modelling of the impact of penicillin consumption on spread of pneumococci. Epidemiology and Infection 139:09, 1351-1360
CrossRef24
Md Yasin Rohani, Norni Mohd Zin, Azura Hussin, Salbiah Haji Nawi, Suhailah Md Hanapiah, Zubaidah Abdul Wahab, Ganeswarie Raj, Norazita Shafie, Ng Pey Peng, Keah K. Chu, Muhhamad Nazri Aziz, Nurahan Maning, Jamilah Said Mohamad, Adom Benjamin, Mohd. Azmi bin Mohd. Salleh, Sabarina Sabihah Zahari, Alex Francis, Norazah Ahmad, Rina Karunakaran. (2011) Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals. Vaccine 29:34, 5688-5693
CrossRef25
David E. Barroso, Daniel Godoy, Terezinha M. P. P. Castiñeiras, Mary M. Tulenko, Maria C. Rebelo, Lee H. Harrison. (2011) β-lactam Resistance, Serotype Distribution, and Genotypes of Meningitis-causing Streptococcus pneumoniae, Rio de Janeiro, Brazil. The Pediatric Infectious Disease Journal1
CrossRef26
J. B. Rosen, A. R. Thomas, C. A. Lexau, A. Reingold, J. L. Hadler, L. H. Harrison, N. M. Bennett, W. Schaffner, M. M. Farley, B. W. Beall, M. R. Moore, . (2011) Geographic Variation in Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccine Introduction in the United States. Clinical Infectious Diseases 53:2, 137-143
CrossRef27
Ido Somech, Ron Dagan, Noga Givon-Lavi, Nurith Porat, Simon Raiz, Alberto Leiberman, Mark Puterman, Nehama Peled, David Greenberg, Eugene Leibovitz. (2011) Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine. Vaccine 29:25, 4202-4209
CrossRef28
P. Chavanet, A. Atale, S. Mahy, C. Neuwirth, E. Varon, H. Dabernat, H. Portier. (2011) Portage nasopharyngé, sensibilités et sérotypes de Streptococcus pneumoniae et Haemophilus influenzae chez les enfants de crèches. Médecine et Maladies Infectieuses 41:6, 307-317
CrossRef29
Tae Hyong Kim, Jennie Johnstone, Mark Loeb. (2011) Vaccine herd effect. Scandinavian Journal of Infectious Diseases1-7
CrossRef30
P. R. Paradiso. (2011) Advances in Pneumococcal Disease Prevention: 13-Valent Pneumococcal Conjugate Vaccine for Infants and Children. Clinical Infectious Diseases 52:10, 1241-1247
CrossRef31
THIAGO LISBOA, GRANT W. WATERER, Y.C. GARY LEE. (2011) Pleural infection: Changing bacteriology and its implications. Respirology 16:4, 598-603
CrossRef32
William P. Hanage, Cynthia J. Bishop, Susan S. Huang, Abbie E. Stevenson, Stephen I. Pelton, Marc Lipsitch, Jonathan A. Finkelstein. (2011) Carried Pneumococci in Massachusetts Children. The Pediatric Infectious Disease Journal 30:4, 302-308
CrossRef33
Jin Yang Baek, Kwan Soo Ko, So Hyun Kim, Cheol-In Kang, Doo Ryeon Chung, Kyong Ran Peck, Jae-Hoon Song. (2011) Comparison of genotypes of Streptococcus pneumoniae serotypes 6A and 6B before and after the introduction of PCV7 vaccination in Korea. Diagnostic Microbiology and Infectious Disease 69:4, 370-375
CrossRef34
Antoni Payeras, Aroa Villoslada, Margarita Garau, María Borras, Antonio Pareja, David Beingolea, Mercedes García-Gasalla, M.D. Gallegos, Carlos José Alonso-Villaverde. (2011) Neumonía neumocócica en la era de la vacuna conjugada heptavalente. Enfermedades Infecciosas y Microbiología Clínica 29:4, 250-256
CrossRef35
Pierre Olivier Lang, Sheila Govind, Jean Pierre Michel, Richard Aspinall, Wayne A. Mitchell. (2011) Immunosenescence: Implications for vaccination programmes in adults. Maturitas 68:4, 322-330
CrossRef36
Tirdad T Zangeneh, Gio Baracco, Jaffar A Al-Tawfiq. (2011) Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. Expert Review of Vaccines 10:3, 345-353
CrossRef37
Bernard Fritzell, Mark A Fletcher. (2011) Pneumococcal polysaccharide–protein (CRM 197 ) conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule. Expert Review of Vaccines 10:3, 263-290
CrossRef38
Anna Skoczyńska, Ewa Sadowy, Katarzyna Bojarska, Janusz Strzelecki, Alicja Kuch, Agnieszka Gołębiewska, Izabela Waśko, Małgorzata Foryś, Mark van der Linden, Waleria Hryniewicz. (2011) The current status of invasive pneumococcal disease in Poland. Vaccine 29:11, 2199-2205
CrossRef39
E David G McIntosh, Ralf R Reinert. (2011) Global prevailing and emerging pediatric pneumococcal serotypes. Expert Review of Vaccines 10:1, 109-129
CrossRef40
Ayesha Mirza, Mobeen H. Rathore. (2011) Immunization Update III. Advances in Pediatrics 58:1, 41-64
CrossRef41
Asunción Fenoll, Lorenzo Aguilar, Maria-Dolores Vicioso, Maria-Jose Gimenez, Olga Robledo, Juan-Jose Granizo. (2011) Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009. BMC Infectious Diseases 11:1, 239
CrossRef42
Yuka Tomita, Akira Okamoto, Keiko Yamada, Testuya Yagi, Yoshinori Hasegawa, Michio Ohta. (2011) A New Microarray System to Detect Streptococcus pneumoniae Serotypes. Journal of Biomedicine and Biotechnology 2011, 1-21
CrossRef43
Elisabeth Autret-Leca, Lamiae Grimaldi-Bensouda, Claire Daubin, Paula Poggi, Anne-Elisabeth Collignon, Annie-Pierre Jonville-Béra. (2011) Heptavalent Pneumococcal Conjugate Vaccine (PCV7): French Survey of Serious Adverse Reactions. Thérapie 66:1, 81-86
CrossRef44
John W. Ogle. 2011. Acute fever without a source in infants and children 3 to 36 months of age. , 178-183.
CrossRef45
Kam Lun Hon, Margaret Ip, Kenneth Lee, Edmund Anthony Nelson, Ka Ho Eric Shea, Yiu Sang Tony Yuen, Ting Fan Leung. (2010) Childhood Pneumococcal Diseases and Serotypes: Can Vaccines Protect?. The Indian Journal of Pediatrics 77:12, 1387-1391
CrossRef46
Salla Laitinen, Martti Vaara, Eeva Salo. (2010) Pneumococcal serotype distribution in invasive paediatric disease in Southern Finland before the introduction of vaccine. Scandinavian Journal of Infectious Diseases 42:11-12, 924-930
CrossRef47
Shasha Zou, Qihui Luo, Zhengli Chen, Anchun Cheng, Mingshu Wang, Dekang Zhu, Renyong Jia, Fei Liu, Xiaoyue Chen, Yi Zhou, Fengjun Bi, Zexia Yang. (2010) Isolation, identification of Streptococcus pneumoniae from infected rhesus monkeys and control efficacy. Journal of Medical Primatology 39:6, 417-423
CrossRef48
(2010) Public health impact of pneumococcal vaccination. International Journal of Infectious Diseases 14, e4-e6
CrossRef49
Michael S. Benninger, Ryan Manz. (2010) The Impact of Vaccination on Rhinosinusitis and Otitis Media. Current Allergy and Asthma Reports 10:6, 411-418
CrossRef50
Susana Chávez-Bueno, Terrence L. Stull. (2010) Pediatric Vaccines on the Horizon. The American Journal of the Medical Sciences 340:3, 226-231
CrossRef51
Dror S. Shouval, Nurith Porat, Ron Dagan, Nathan Keller, Efraim Bilavsky, Yoram Sivan, Jacob Amir. (2010) Bacteremia caused by a highly-resistant Streptococcus pneumoniae serotype 19A circulating in a daycare center. International Journal of Infectious Diseases 14, e253-e255
CrossRef52
P. Iraurgui, M. J. Torres, A. Gandia, I. Vazquez, E. G. Cabrera, I. Obando, J. Garnacho, J. Aznar. (2010) Modified sequential multiplex PCR for determining capsular serotypes of invasive pneumococci recovered from Seville. Clinical Microbiology and Infection 16:9, 1504-1507
CrossRef53
Peter Davey, Jacqueline Sneddon, Dilip Nathwani. (2010) Overview of strategies for overcoming the challenge of antimicrobial resistance. Expert Review of Clinical Pharmacology 3:5, 667-686
CrossRef54
Sandra I. Aguiar, Maria J. Brito, José Gonçalo-Marques, José Melo-Cristino, Mário Ramirez. (2010) Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine 28:32, 5167-5173
CrossRef55
Gili Regev-Yochay, William P. Hanage, Krzysztof Trzcinski, Sheryl L. Rifas-Shiman, Grace Lee, Andrew Bessolo, Susan S. Huang, Stephen I. Pelton, Alexander J. McAdam, Jonathan A. Finkelstein, Marc Lipsitch, Richard Malley. (2010) Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine 28:30, 4842-4846
CrossRef56
C. Colijn, T. Cohen, C. Fraser, W. Hanage, E. Goldstein, N. Givon-Lavi, R. Dagan, M. Lipsitch. (2010) What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae?. Journal of The Royal Society Interface 7:47, 905-919
CrossRef57
Mark D. Joffe, Elizabeth R. Alpern. (2010) Occult Pneumococcal Bacteremia. Pediatric Emergency Care 26:6, 448-454
CrossRef58
Rene Reinert, Michael R. Jacobs, Sheldon L. Kaplan. (2010) Pneumococcal disease caused by serotype 19A: Review of the literature and implications for future vaccine development. Vaccine 28:26, 4249-4259
CrossRef59
Sungkyoung Lee, Kwangjun Lee, Yeonho Kang, Songmee Bae. (2010) Prevalence of Serotype and Multidrug-Resistance of Streptococcus pneumoniae Respiratory Tract Isolates in 265 Adults and 36 Children in Korea, 2002–2005. Microbial Drug Resistance 16:2, 135-142
CrossRef60
Dorothee M. Kieninger, Kathrin Kueper, Katrin Steul, Christine Juergens, Norbert Ahlers, Sherryl Baker, Kathrin U. Jansen, Carmel Devlin, William C. Gruber, Emilio A. Emini, Daniel A. Scott. (2010) Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 28:25, 4192-4203
CrossRef61
Thierry Van Effelterre, Matthew R. Moore, Frederik Fierens, Cynthia G. Whitney, Lisa White, Stephen I. Pelton, William P. Hausdorff. (2010) A dynamic model of pneumococcal infection in the United States: Implications for prevention through vaccination. Vaccine 28:21, 3650-3660
CrossRef62
J. Liñares, C. Ardanuy, R. Pallares, A. Fenoll. (2010) Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clinical Microbiology and Infection 16:5, 402-410
CrossRef63
Matthias Imöhl, Ralf René Reinert, Mark van der Linden. (2010) Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. International Journal of Medical Microbiology 300:4, 237-247
CrossRef64
E. Theodoratou, S. Johnson, A. Jhass, S. A. Madhi, A. Clark, C. Boschi-Pinto, S. Bhopal, I. Rudan, H. Campbell. (2010) The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. International Journal of Epidemiology 39:Supplement 1, i172-i185
CrossRef65
Daniel J. Isaacman, E. David McIntosh, Ralf R. Reinert. (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. International Journal of Infectious Diseases 14:3, e197-e209
CrossRef66
Didrik F. Vestrheim, E. Arne Høiby, Marianne R. Bergsaker, Karin Rønning, Ingeborg S. Aaberge, Dominique A. Caugant. (2010) Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 28:10, 2214-2221
CrossRef67
R. E. Gertz, Z. Li, F. C. Pimenta, D. Jackson, B. A. Juni, R. Lynfield, J. H. Jorgensen, M. da Gloria Carvalho, B. W. Beall. (2010) Increased Penicillin Nonsusceptibility of Nonvaccine-Serotype Invasive Pneumococci Other than Serotypes 19A and 6A in Post-7-Valent Conjugate Vaccine Era. Journal of Infectious Diseases 201:5, 770-775
CrossRef68
Cláudia Calado, Pedro Nunes, Luísa Pereira, Teresa Nunes, Celeste Barreto, Teresa Bandeira. (2010) Estarão diferentes as pneumonias agudas adquiridas na comunidade com internamento hospitalar em idade pediátrica na última década?. Revista Portuguesa de Pneumologia (English Edition) 16:2, 287-305
CrossRef69
Tina Q Tan. (2010) Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA. Expert Review of Anti-infective Therapy 8:2, 117-125
CrossRef70
James A Hedrick. (2010) Community-acquired upper respiratory tract infections and the role of third-generation oral cephalosporins. Expert Review of Anti-infective Therapy 8:1, 15-21
CrossRef71
Robertino M. Mera, Linda A. Miller, Heather Amrine-Madsen, Daniel F. Sahm. (2009) The Impact of the Pneumococcal Conjugate Vaccine on Antimicrobial Resistance in the United States Since 1996: Evidence for a Significant Rebound by 2007 in Many Classes of Antibiotics. Microbial Drug Resistance 15:4, 261-268
CrossRef72
L.C. Bravo. (2009) Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 27:52, 7282-7291
CrossRef73
O. R. REMPEL, K. B. LAUPLAND. (2009) Surveillance for antimicrobial resistant organisms: potential sources and magnitude of bias. Epidemiology and Infection 137:12, 1665
CrossRef74
W.P. Hausdorff, R. Dagan, F. Beckers, L. Schuerman. (2009) Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27:52, 7257-7269
CrossRef75
D. Adam, A. Busse. (2009) Pneumokokkenkonjugatimpfstoffe. Monatsschrift Kinderheilkunde 157:12, 1252-1256
CrossRef76
M. Guevara, A. Barricarte, A. Gil-Setas, J. J. García-Irure, X. Beristain, L. Torroba, A. Petit, M. E. Polo Vigas, A. Aguinaga, J. Castilla. (2009) Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clinical Microbiology and Infection 15:11, 1013-1019
CrossRef77
L. Salleras, A. Domínguez, P. Ciruela, C. Izquierdo, E. Navas, N. Torner, E. Borras. (2009) Changes in serotypes causing invasive pneumococcal disease (2005-2007 vs. 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clinical Microbiology and Infection 15:11, 997-1001
CrossRef78
Dieter Adam. (2009) Issues in pneumococcal disease and pneumococcal conjugate vaccines: Highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9–13, 2009. Vaccine 27:50, 7133-7137
CrossRef79
R. Sá-Leão, S. Nunes, A. Brito-Avô, N. Frazão, A. S. Simões, M. I. Crisóstomo, A. C. S. Paulo, J. Saldanha, I. Santos-Sanches, H. de Lencastre. (2009) Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clinical Microbiology and Infection 15:11, 1002-1007
CrossRef80
Chonnamet Techasaensiri, Allison F. Messina, Kathy Katz, Naveed Ahmad, Rong Huang, George H. McCracken. (2009) Epidemiology and Evolution of Invasive Pneumococcal Disease Caused by Multidrug Resistant Serotypes of 19A in the 8 Years After Implementation of Pneumococcal Conjugate Vaccine Immunization in Dallas, Texas. The Pediatric Infectious Disease Journal1
CrossRef81
Rolando Ulloa-Gutierrez, Marcela Hernández-de Mezerville. (2009) 27th Annual Meeting of the European Society for Paediatric Infectious Diseases. Expert Review of Anti-infective Therapy 7:8, 937-939
CrossRef82
Louis B Rice. (2009) The clinical consequences of antimicrobial resistance. Current Opinion in Microbiology 12:5, 476-481
CrossRef83
Hanna Nohynek, Shabir Madhi, Carlos G. Grijalva. (2009) Childhood Bacterial Respiratory Diseases. The Pediatric Infectious Disease Journal 28, S127-S132
CrossRef84
Thomas M. File, Donald E. Low. (2009) Unmet Needs for the Treatment of Moderate-to-Severe or Hospitalized Community-Acquired Pneumonia. Clinical Pulmonary Medicine 16:5, 243-251
CrossRef85
Yu-Chia Hsieh, Pen-Yi Lin, Cheng-Hsun Chiu, Yhu-Chering Huang, Kuang-Yi Chang, Chun-Hsing Liao, Nan-Chang Chiu, Yin-Ching Chuang, Po-Yen Chen, Shan-Chwen Chang, Jien-Wei Liu, Muh-Yong Yen, Jen-Hsien Wang, Cheng-Yi Liu, Tzou-Yien Lin. (2009) National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: Emergence of serotype 19A with high invasive potential. Vaccine 27:40, 5513-5518
CrossRef86
K. Debbache, E. Varon, Y. Hicheri, P. Legrand, J-L. Donay, P. Ribaud, C. Cordonnier. (2009) The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines?. Clinical Microbiology and Infection 15:9, 865-868
CrossRef87
Laurent Dortet, Marie-Cécile Ploy, Claire Poyart, Josette Raymond. (2009) Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagnostic Microbiology and Infectious Disease 65:1, 49-57
CrossRef88
Ener Cagri Dinleyici, Zeynel Abidin Yargic. (2009) Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Review of Vaccines 8:8, 977-986
CrossRef89
Stephen Obaro. (2009) Seven-valent pneumococcal conjugate vaccines for developing countries. Expert Review of Vaccines 8:8, 1051-1061
CrossRef90
Ron Dagan. (2009) New insights on pneumococcal disease: What we have learned over the past decade. Vaccine 27, C3-C5
CrossRef91
M. Teresa Valenzuela, Ciro de Quadros. (2009) Antibiotic resistance in Latin America: A cause for alarm. Vaccine 27, C25-C28
CrossRef92
Renuka Verma, Margaret C. Fisher. (2009) Bacterial meningitis vaccines: Not just for kids. Current Infectious Disease Reports 11:4, 302-308
CrossRef93
E. Pérez-Trallero, J. M. Marimon, M. Ercibengoa, D. Vicente, E. G. Pérez-Yarza. (2009) Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. European Journal of Clinical Microbiology & Infectious Diseases 28:7, 731-738
CrossRef94
W. P. Hanage, C. Fraser, J. Tang, T. R. Connor, J. Corander. (2009) Hyper-Recombination, Diversity, and Antibiotic Resistance in Pneumococcus. Science 324:5933, 1454-1457
CrossRef95
Claire M. Smith, Carla Lo Passo, Angela Scuderi, Jan Kolberg, Helen Baxendale, David Goldblatt, Marco R. Oggioni, Franco Felici, Peter W. Andrew. (2009) Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae. European Journal of Immunology 39:6, 1527-1535
CrossRef96
J. H. FLORY, M. JOFFE, N. O. FISHMAN, P. H. EDELSTEIN, J. P. METLAY. (2009) Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiology and Infection 137:05, 717
CrossRef97
Dror S. Shouval, David Greenberg, Noga Givon-Lavi, Nurith Porat, Ron Dagan. (2009) Serotype Coverage of Invasive and Mucosal Pneumococcal Disease in Israeli Children Younger Than 3 Years by Various Pneumococcal Conjugate Vaccines. The Pediatric Infectious Disease Journal 28:4, 277-282
CrossRef98
R. Dagan. (2009) Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clinical Microbiology and Infection 15, 16-20
CrossRef99
R. R. Reinert. (2009) The public health ramifications of pneumococcal resistance. Clinical Microbiology and Infection 15, 1-3
CrossRef100
M. A. Borg, E. Tiemersma, E. Scicluna, N. van de Sande-Bruinsma, M. de Kraker, J. Monen, H. Grundmann, . (2009) Prevalence of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae isolates reported by laboratories in the southern and eastern Mediterranean region. Clinical Microbiology and Infection 15:3, 232-237
CrossRef101
Jay B Varkey, Anita B Varkey, Basil Varkey. (2009) Prophylactic vaccinations in chronic obstructive pulmonary disease: current status. Current Opinion in Pulmonary Medicine 15:2, 90-99
CrossRef102
Moon H. Nahm, Jisheng Lin, Jonathan A. Finkelstein, Stephen I. Pelton. (2009) Increase in the Prevalence of the Newly Discovered Pneumococcal Serotype 6C in the Nasopharynx after Introduction of Pneumococcal Conjugate Vaccine. The Journal of Infectious Diseases 199:3, 320-325
CrossRef103
Åsa Karlström, Kelli L. Boyd, B. Keith English, Jonathan A. McCullers. (2009) Treatment with Protein Synthesis Inhibitors Improves Outcomes of Secondary Bacterial Pneumonia after Influenza. The Journal of Infectious Diseases 199:3, 311-319
CrossRef104
Sandra S. Richter, Kristopher P. Heilmann, Cassie L. Dohrn, Fathollah Riahi, Susan E. Beekmann, Gary V. Doern. (2009) Changing Epidemiology of Antimicrobial‐Resistant Streptococcus pneumoniae in the United States, 2004–2005. Clinical Infectious Diseases 48:3, e23-e33
CrossRef105
Lise E. Nigrovic, Richard Malley, Nathan Kuppermann. (2009) Cerebrospinal Fluid Pleocytosis in Children in the Era of Bacterial Conjugate Vaccines. Pediatric Emergency Care 25:2, 112-117
CrossRef106
C. J. Harrison, C. Woods, G. Stout, B. Martin, R. Selvarangan. (2009) Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics. Journal of Antimicrobial Chemotherapy 63:3, 511-519
CrossRef107
Hsu, Heather E., Shutt, Kathleen A., Moore, Matthew R., Beall, Bernard W., Bennett, Nancy M., Craig, Allen S., Farley, Monica M., Jorgensen, James H., Lexau, Catherine A., Petit, Susan, Reingold, Arthur, Schaffner, William, Thomas, Ann, Whitney, Cynthia G., Harrison, Lee H., . (2009) Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis. New England Journal of Medicine 360:3, 244-256
Full Text108
G. Gherardi, F. D’Ambrosio, M. Monaco, R. Camilli, L. Florio, F. D’Ancona, G. Dicuonzo, A. Pantosti. (2009) Population structure of invasive Streptococcus pneumoniae isolates in Italy prior to the implementation of the 7-valent conjugate vaccine (1999–2003). European Journal of Clinical Microbiology & Infectious Diseases 28:1, 99-103
CrossRef109
Fernando Artiles, Iballa Horcajada, Ana María Cañas, Isabel Álamo, Ana Bordes, Agustín González, Milagrosa Santana, Bernardo Lafarga. (2009) Aspectos epidemiológicos de la enfermedad neumocócica invasiva antes y después del uso de la vacuna neumocócica conjugada en Gran Canaria. Enfermedades Infecciosas y Microbiología Clínica 27:1, 14-21
CrossRef110
William A. Ciccotelli, Susan M. Poutanen, Manaf Alqahtani, Shaun K. Morris, Peter Cox, Donald E. Low, Dylan R. Pillai, Mary Anne Opavsky. (2009) A New Twist on an Old Problem. The Pediatric Infectious Disease Journal 28:1, 74-75
CrossRef111
Piotr Albrecht, Marian Patrzałek, Maria Kotowska, Andrzej Radzikowski. (2009) Kliniczne i praktyczne efekty szczepień skoniugowaną szczepionką pneumokokową w zapobieganiu inwazyjnej chorobie pneumokokowej, zapaleniom płuc i ucha środkowego u dzieci w świetle doświadczeń światowych i polskich. Pediatria Polska 84:1, 3-12
CrossRef112
Carmen Ardanuy, Fe Tubau, Román Pallares, Laura Calatayud, María Angeles Domínguez, Dora Rolo, Inmaculada Grau, Rogelio Martín, Josefina Liñares. (2009) Epidemiology of Invasive Pneumococcal Disease among Adult Patients in Barcelona Before and After Pediatric 7‐Valent Pneumococcal Conjugate Vaccine Introduction, 1997–2007. Clinical Infectious Diseases 48:1, 57-64
CrossRef113
In H. Park, Matthew R. Moore, John J. Treanor, Stephen I. Pelton, Tamara Pilishvili, Bernard Beall, Mark A. Shelly, Barbara E. Mahon, Moon H. Nahm, . (2008) Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C. The Journal of Infectious Diseases 198:12, 1818-1822
CrossRef114
Ron Dagan, Keith P Klugman. (2008) Impact of conjugate pneumococcal vaccines on antibiotic resistance. The Lancet Infectious Diseases 8:12, 785-795
CrossRef115
P. Courvalin. (2008) Can pharmacokinetic-pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?. Clinical Microbiology and Infection 14:11, 989-994
CrossRef116
Ener Cagri Dinleyici, Zeynel Abidin Yargic. (2008) Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Review of Vaccines 7:9, 1367-1394
CrossRef117
Brigitte Dunais, Pascale Bruno, Hélène Carsenti-Dellamonica, Pia Touboul, Pierre Dellamonica, Christian Pradier. (2008) TRENDS IN NASOPHARYNGEAL CARRIAGE OF STREPTOCOCCUS PNEUMONIAE AMONG CHILDREN ATTENDING DAYCARE CENTERS IN SOUTHEASTERN FRANCE FROM 1999 TO 2006. The Pediatric Infectious Disease Journal 27:11, 1033-1035
CrossRef118
Thomas M. File. (2008) Drug-Resistant Streptococcus pneumoniae for Community-Acquired Pneumonia. Infectious Diseases in Clinical Practice 16:6, 343-344
CrossRef119
Daniel M. Musher, Adriana M. Rueda, Moon H. Nahm, Edward A. Graviss, Maria C. Rodriguez‐Barradas. (2008) Initial and Subsequent Response to Pneumococcal Polysaccharide and Protein‐Conjugate Vaccines Administered Sequentially to Adults Who Have Recovered from Pneumococcal Pneumonia. The Journal of Infectious Diseases 198:7, 1019-1027
CrossRef120
Juan Carlos Sanz, Isabel Wilhelmi, Nazaret Méndez, Asunción Fenoll. (2008) Evaluación de una técnica de aglutinación por látex para la serotipificación de Streptococcus pneumoniae. Enfermedades Infecciosas y Microbiología Clínica 26:8, 531-533
CrossRef121
J. J. Fitzsimons, A. L. Chong, M. T. Cafferkey, K. M. Butler. (2008) Invasive pneumococcal disease in children in Ireland—the anticipated benefit of conjugate pneumococcal vaccination. Irish Journal of Medical Science 177:3, 225-231
CrossRef122
Lesley Tilson, Cara Usher, Karina Butler, John Fitzsimons, Fiona O'Hare, Suzanne Cotter, Darina O'Flanagan, Howard Johnson, Michael Barry. (2008) Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland. Value in Health 11:5, 898-903
CrossRef123
David Greenberg, Noga Givon-Lavi, Amir Z. Sharf, Daniel Vardy, Ron Dagan. (2008) The Association Between Antibiotic Use in the Community and Nasopharyngeal Carriage of Antibiotic-Resistant Streptococcus pneumoniae in Bedouin Children. The Pediatric Infectious Disease Journal 27:9, 776-782
CrossRef124
Mary Pao, Esperanza B. Papadopoulos, Joanne Chou, Heller Glenn, Hugo Castro-Malaspina, Ann A. Jakubowski, Nancy A. Kernan, Miguel A. Perales, Susan Prokop, Andromachi Scaradavou, Marcel R. vanDenBrink, James W. Young, Richard J. O'Reilly, Trudy N. Small. (2008) Response to Pneumococcal (PNCRM7) and Haemophilus Influenzae Conjugate Vaccines (HIB) in Pediatric and Adult Recipients of an Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biology of Blood and Marrow Transplantation 14:9, 1022-1030
CrossRef125
Mathias W. Pletz, Ulrich Maus, Norbert Krug, Tobias Welte, Hartmut Lode. (2008) Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents 32:3, 199-206
CrossRef126
S. I. Aguiar, I. Serrano, F. R. Pinto, J. Melo-Cristino, M. Ramirez, . (2008) Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clinical Microbiology and Infection 14:9, 835-843
CrossRef127
Joris J. van Driel, Vincent Bekker, Lodewijk Spanjaard, Arie van der Ende, Taco W. Kuijpers. (2008) Epidemiologic and Microbiologic Characteristics of Recurrent Bacterial and Fungal Meningitis in The Netherlands, 1988–2005. Clinical Infectious Diseases 47:5, e42-e51
CrossRef128
Todd A. Davies, Y. Cheung Yee, Karen Bush, Dan Sahm, Alan Evangelista, Raul Goldschmidt. (2008) Effects of the 7-Valent Pneumococcal Conjugate Vaccine on U.S. Levofloxacin-Resistant Streptococcus pneumoniae. Microbial Drug Resistance 14:3, 187-196
CrossRef129
Rochelle Lacapa, Sandra J. Bliss, Francene Larzelere‐Hinton, Kathryn J. Eagle, Debra J. McGinty, Alan J. Parkinson, Mathuram Santosham, Mariddie J. Craig, Katherine L. O’Brien. (2008) Changing Epidemiology of Invasive Pneumococcal Disease among White Mountain Apache Persons in the Era of the Pneumococcal Conjugate Vaccine. Clinical Infectious Diseases 47:4, 476-484
CrossRef130
Oguz Resat Sipahi. (2008) Economics of antibiotic resistance. Expert Review of Anti-infective Therapy 6:4, 523-539
CrossRef131
S. Yu, K. Yao, X. Shen, W. Zhang, X. Liu, Y. Yang. (2008) Serogroup distribution and antimicrobial resistance of nasopharyngeal isolates of Streptococcus pneumoniae among Beijing children with upper respiratory infections (2000–2005). European Journal of Clinical Microbiology & Infectious Diseases 27:8, 649-655
CrossRef132
D. Sánchez-Tatay, L. A. Arroyo, D. Tarragó, M. J. Lirola, A. Porras, A. Fenoll, W. P. Hausdorff, A. B. Brueggemann, I. Obando. (2008) Antibiotic susceptibility and molecular epidemiology of nasopharyngeal pneumococci from Spanish children. Clinical Microbiology and Infection 14:8, 797-801
CrossRef133
Sigurveig Th. Sigurdardottir, Katrin Davidsdottir, Vilhjalmur A. Arason, Olof Jonsdottir, France Laudat, William C. Gruber, Ingileif Jonsdottir. (2008) Safety and immunogenicity of CRM197-conjugated pneumococcal–meningococcal C combination vaccine (9vPnC–MnCC) whether given in two or three primary doses. Vaccine 26:33, 4178-4186
CrossRef134
Fulvio Braido, Michele Bellotti, Andrea De Maria, Mario Cazzola, Giorgio Walter Canonica. (2008) The role of Pneumococcal vaccine. Pulmonary Pharmacology & Therapeutics 21:4, 608-615
CrossRef135
Simon Rückinger, Rüdiger von Kries, Ralf René Reinert, Mark van der Linden, Annette Siedler. (2008) Childhood invasive pneumococcal disease in Germany between 1997 and 2003: Variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Vaccine 26:32, 3984-3986
CrossRef136
Yudong Liu, Hui Wang, Minjun Chen, Ziyong Sun, Renzhen Zhao, Li Zhang, Huiyun Wang, Hong Zhang, Luoping Wang, Yunzhuo Chu, Yong Liu, Yuxing Ni. (2008) Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagnostic Microbiology and Infectious Disease 61:3, 256-263
CrossRef137
Nicole Wolter, Anne von Gottberg, Mignon du Plessis, Linda de Gouveia, Keith P. Klugman. (2008) Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000–2005. International Journal of Antimicrobial Agents 32:1, 62-67
CrossRef138
Lise E. Nigrovic, Nathan Kuppermann, Richard Malley, . (2008) Children with Bacterial Meningitis Presenting to the Emergency Department during the Pneumococcal Conjugate Vaccine Era. Academic Emergency Medicine 15:6, 522-528
CrossRef139
Chiaojung Jillian Tsai, Marie R. Griffin, J. Pekka Nuorti, Carlos G. Grijalva. (2008) Changing Epidemiology of Pneumococcal Meningitis after the Introduction of Pneumococcal Conjugate Vaccine in the United States. Clinical Infectious Diseases 46:11, 1664-1672
CrossRef140
Ron Dagan. (2008) Use of Pneumococcal Conjugate Vaccine to Decrease Rates of Bacterial Meningitis. Clinical Infectious Diseases 46:11, 1673-1676
CrossRef141
Chia-Yin Chong, Thoon Koh-Cheng, Mok Yee-Hui, Tee Wen-Sim Nancy. (2008) Invasive Pneumococcal disease in Singapore children. Vaccine 26:27-28, 3427-3431
CrossRef142
Matthew E. Falagas, Petros I. Rafailidis, Gregory C. Makris. (2008) Bacterial interference for the prevention and treatment of infections. International Journal of Antimicrobial Agents 31:6, 518-522
CrossRef143
Ioanna N. Grivea, Maria Panagiotou, Alexandra G. Tsantouli, George A. Syrogiannopoulos. (2008) Impact of Heptavalent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of Penicillin-Resistant Streptococcus pneumoniae Among Day-Care Center Attendees in Central Greece. The Pediatric Infectious Disease Journal 27:6, 519-525
CrossRef144
Clayton Chiu, Greta Ridley, Robert Menzies, Peter McIntyre. (2008) Update on childhood pneumococcal vaccination. Pediatric Health 2:3, 351-365
CrossRef145
(2008) Raising the profile of pneumococcal disease. Internal Medicine Journal 38:6a, 381-383
CrossRef146
Robertino Mera, Linda A. Miller, Thomas R. Fritsche, Ronald N. Jones. (2008) Serotype Replacement and Multiple Resistance in Streptococcus pneumoniae After the Introduction of the Conjugate Pneumococcal Vaccine. Microbial Drug Resistance 14:2, 101-107
CrossRef147
Eugene Leibovitz. (2008) The effect of vaccination on Streptococcus pneumoniae resistance. Current Infectious Disease Reports 10:3, 182-191
CrossRef148
Catherine A. Lexau. (2008) The changing epidemiology of pneumococcal pulmonary disease in the era of the heptavalent vaccine. Current Infectious Disease Reports 10:3, 229-235
CrossRef149
Anne Schuchat, Beth P Bell. (2008) Monitoring the impact of vaccines postlicensure: new challenges, new opportunities. Expert Review of Vaccines 7:4, 437-456
CrossRef150
Cindy R. Friedman, Cynthia G. Whitney. (2008) It's Time for a Change in Practice: Reducing Antibiotic Use Can Alter Antibiotic Resistance. The Journal of Infectious Diseases 197:8, 1082-1083
CrossRef151
Andrés de Roux, B. Schmöele‐Thoma, G. R. Siber, J. G. Hackell, A. Kuhnke, N. Ahlers, S. A. Baker, A. Razmpour, E. A. Emini, P. D. Fernsten, W. C. Gruber, S. Lockhart, O. Burkhardt, T. Welte, H. M. Lode. (2008) Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory. Clinical Infectious Diseases 46:7, 1015-1023
CrossRef152
Emilia Cercenado, Javier Garau, Benito Almirante, José Ramón Azanza, Rafael Cantón, Ramón Cisterna, José María Eiros, Carmen Fariñas, Jesús Fortún, Francisco Gudiol, José Mensa, Jerónimo Pachón, Álvaro Pascual, José Luis Pérez, Alejandro Rodríguez, Miguel Sánchez, Jordi Vila. (2008) Update on bacterial pathogens: virulence and resistance. Enfermedades Infecciosas y Microbiología Clínica 26, 3-21
CrossRef153
Matthew R. Moore, Robert E. Gertz, Jr., Robyn L. Woodbury, Genevieve A. Barkocy‐Gallagher, William Schaffner, Catherine Lexau, Kenneth Gershman, Arthur Reingold, Monica Farley, Lee H. Harrison, James L. Hadler, Nancy M. Bennett, Ann R. Thomas, Lesley McGee, Tamara Pilishvili, Angela B. Brueggemann, Cynthia G. Whitney, James H. Jorgensen, Bernard Beall. (2008) Population Snapshot of Emergent Streptococcus pneumoniae Serotype 19A in the United States, 2005. The Journal of Infectious Diseases 197:7, 1016-1027
CrossRef154
H. M. HEFFERNAN, D. R. MARTIN, R. E. WOODHOUSE, J. MORGAN, T. K. BLACKMORE. (2008) Invasive pneumococcal disease in New Zealand 1998–2005: capsular serotypes and antimicrobial resistance. Epidemiology and Infection 136:03,
CrossRef155
(2008) Emergence of Antimicrobial-Resistant Serotype 19A Streptococcus pneumoniae—Massachusetts, 2001-2006. Annals of Emergency Medicine 51:3, 312-314
CrossRef156
E. Bingen, C. Levy, E. Varon, F. Rocque, M. Boucherat, P. d’Athis, Y. Aujard, R. Cohen, . (2008) Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. European Journal of Clinical Microbiology & Infectious Diseases 27:3, 191-199
CrossRef157
L. Pemba, S. Charalambous, A. von Gottberg, B. Magadla, V. Moloi, O. Seabi, A. Wasas, K.P. Klugman, R.E. Chaisson, K. Fielding, G.J. Churchyard, A.D. Grant. (2008) Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. Journal of Infection 56:3, 171-178
CrossRef158
Louis B. Rice, John G. Bartlett, Donald E. Craven, Dennis L. Stevens, Robert C. Moellering, George M. Eliopoulos. (2008) Emerging Treatments for Resistant Bacterial Infections and Pathogen-Focused Therapy. Infectious Diseases in Clinical Practice 16:Suppl. 1, S1-S20
CrossRef159
Carlos G Grijalva, Marie R Griffin. (2008) Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Review of Vaccines 7:1, 83-95
CrossRef160
William P Hanage. (2008) Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiology 3:1, 23-30
CrossRef161
C. Munoz-Almagro, I. Jordan, A. Gene, C. Latorre, J. J. Garcia-Garcia, R. Pallares. (2008) Emergence of Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes in the Era of 7-Valent Conjugate Vaccine. Clinical Infectious Diseases 46:2, 174-182
CrossRef162
Craig Williams, Robert Masterton. (2008) Pneumococcal immunisation in the 21st century. Journal of Infection 56:1, 13-19
CrossRef163
D. Schiff. (2008) Multiresistant Pneumococci in Otitis Media. AAP Grand Rounds 19:1, 4-4
CrossRef164
Peter Klein Klouwenberg, Louis Bont. (2008) Neonatal and Infantile Immune Responses to Encapsulated Bacteria and Conjugate Vaccines. Clinical and Developmental Immunology 2008, 1-10
CrossRef165
Eunhwa Choi. (2008) Direct and Indirect Effects of Pneumococcal Protein Conjugate Vaccine. Journal of the Korean Medical Association 51:2, 119
CrossRef166
Susan E. Crawford, Robert S. Daum. 2008. Bacterial Pneumonia, Lung Abscess, and Empyema. , 501-553.
CrossRef167
Isabel de Miguel-Martínez, Ángel Ramos-Macías, Silvia Borkoski Barreiro. (2008) Efecto de la vacuna heptavalente contra Streptococcus pneumoniae en niños con implante coclear. Acta Otorrinolaringológica Española 59:1, 2-5
CrossRef168
Jesús Ruiz-Contreras. (2008) Vacunas neumocócicas conjugadas: presente y futuro. Enfermedades Infecciosas y Microbiología Clínica 26, 48-55
CrossRef169
Isabel de Miguel-Martínez, Ángel Ramos-Macías, Silvia Borkoski Barreiro. (2008) Efficacy of Heptavalent Pneumococcal Conjugate Vaccine in Children With Cochlear Implant. Acta Otorrinolaringologica (English Edition) 59:1, 2-5
CrossRef170
Christopher Gerard Dowson, Krzysztof Trzcinski. 2007. Evolution and Epidemiology of Antibiotic-Resistant Pneumococci. , 229-254.
CrossRef171
Arjun Srinivasan, Cindy Friedman. 2007. Public Health Responses to Antimicrobial Resistance in Outpatient and Inpatient Settings. , 377-407.
CrossRef172
L. C. Santos, J. Simões, M. Severo, J. Vazquez, H. Lecour. (2007) Bacterial Meningitis in an Urban Area: Etiologic Study and Prognostic Factors. Infection 35:6, 406-413
CrossRef173
Heather J. Zar. (2007) Child lung health: A global concern. An introduction to the series. Pediatric Pulmonology 42:12, 1085-1086
CrossRef174
Rafael Cantón, Serhat Unal, David J. Farrell. (2007) Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1–5 (1999–2004). International Journal of Antimicrobial Agents 30:6, 546-550
CrossRef175
Paul Ishimine. (2007) The Evolving Approach to the Young Child Who Has Fever and No Obvious Source. Emergency Medicine Clinics of North America 25:4, 1087-1115
CrossRef176
Chih-Jung Chen, Yhu-Chering Huang, Lin-Hui Su, Tzou-Yien Lin. (2007) Nasal carriage of Streptococcus pneumoniae in healthy children and adults in northern Taiwan. Diagnostic Microbiology and Infectious Disease 59:3, 265-269
CrossRef177
C. Myers, Alain Gervaix. (2007) Streptococcus pneumoniae bacteraemia in children. International Journal of Antimicrobial Agents 30, 24-28
CrossRef178
Nam-Hee Kim, Jina Lee, Sang Jeong Lee, Hyunju Lee, Kyung-Hyo Kim, Su-Eun Park, Hoan-Jong Lee. (2007) Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein conjugate; Prevenar™) in Korean infants: Differences that are found in Asian children. Vaccine 25:45, 7858-7865
CrossRef179
M. Lipsitch, J. J O'Hagan. (2007) Patterns of antigenic diversity and the mechanisms that maintain them. Journal of The Royal Society Interface 4:16, 787-802
CrossRef180
Lesley McGee. (2007) The coming of age of niche vaccines?. Current Opinion in Microbiology 10:5, 473-478
CrossRef181
M. Penaranda, V. Falco, A. Payeras, Q. Jordano, A. Curran, A. Pareja, G. Samperiz, D. Dalmau, E. Ribera, M. Riera. (2007) Effectiveness of Polysaccharide Pneumococcal Vaccine in HIV-Infected Patients: a Case-Control Study. Clinical Infectious Diseases 45:7, e82-e87
CrossRef182
Susan Shoshana Weisberg. (2007) Pneumococcus. Disease-a-Month 53:10, 495-502
CrossRef183
David Felmingham, Rafael Cantón, Stephen G. Jenkins. (2007) Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001–2004. Journal of Infection 55:2, 111-118
CrossRef184
Salvador Bello Dronda, Manuel Vilá Justribó. (2007) ¿Seguiremos teniendo antibióticos mañana?. Archivos de Bronconeumología 43:8, 450-459
CrossRef185
David C. Spencer. (2007) Preventing bacterial disease in the HIV-infected of sub-saharan africa: The role of cotrimoxazole and the pneumococcal vaccines. Current HIV/AIDS Reports 4:3, 141-146
CrossRef186
MarkAlain Dery, Rodrigo Hasbun. (2007) Changing epidemiology of bacterial meningitis. Current Infectious Disease Reports 9:4, 301-307
CrossRef187
Stefan H.E. Kaufmann. (2007) The contribution of immunology to the rational design of novel antibacterial vaccines. Nature Reviews Microbiology 5:7, 491-504
CrossRef188
Martijn Weisfelt, Jan de Gans, Diederik van de Beek. (2007) Bacterial meningitis: a review of effective pharmacotherapy. Expert Opinion on Pharmacotherapy 8:10, 1493-1504
CrossRef189
W. C. Albrich, W. Baughman, B. Schmotzer, M. M. Farley. (2007) Changing Characteristics of Invasive Pneumococcal Disease in Metropolitan Atlanta, Georgia, after Introduction of a 7-Valent Pneumococcal Conjugate Vaccine. Clinical Infectious Diseases 44:12, 1569-1576
CrossRef190
Aurelio Barricarte, Alberto Gil-Setas, Luis Torroba, Jesús Castilla, Alba Petit, Isabel Polo, Maite Arriazu, Fátima Irisarri, Manuel García Cenoz. (2007) Enfermedad neumocócica invasiva en la población menor de 5 años de edad de Navarra (2000-2005): impacto de la vacuna conjugada. Medicina Clínica 129:2, 41-45
CrossRef191
Bernard Beall. (2007) Vaccination with the pneumococcal 7-valent conjugate: a successful experiment but the species is adapting. Expert Review of Vaccines 6:3, 297-300
CrossRef192
Allison F. Messina, Kathy Katz-Gaynor, Theresa Barton, Naveed Ahmad, Faryal Ghaffar, David Rasko, George H. McCracken. (2007) Impact of the Pneumococcal Conjugate Vaccine on Serotype Distribution and Antimicrobial Resistance of Invasive Streptococcus pneumoniae Isolates in Dallas, TX, Children From 1999 Through 2005. The Pediatric Infectious Disease Journal 26:6, 461-467
CrossRef193
Keith P. Klugman, Lesley McGee. (2007) Resurgence of the Multiresistant Pneumococcus in the United States: A Commentary. The Pediatric Infectious Disease Journal 26:6, 473-474
CrossRef194
M. H. Steinberg. (2007) Pneumococcus and Sickle Cell Disease: The Beginning of the End?. Clinical Infectious Diseases 44:11, 1434-1435
CrossRef195
David M. Livermore. (2007) Introduction: the challenge of multiresistance. International Journal of Antimicrobial Agents 29, S1-S7
CrossRef196
Li Han Lim, Way Seah Lee, Navaratnam Parasakthi. (2007) Childhood invasive pneumococcal disease: A hospital-based study from Malaysia. Journal of Paediatrics and Child Health 43:5, 366-369
CrossRef197
Arunabh Talwar, Hans Lee, Alan Fein. (2007) Community-acquired pneumonia: what is relevant and what is not?. Current Opinion in Pulmonary Medicine 13:3, 177-185
CrossRef198
D.B. Blossom, S.M. Cordeiro, S. Bajaksouzian, M.L. Joloba, C. Kityo, C.C. Whalen, R.A. Salata, M.R. Jacobs. (2007) Characterization of Penicillin Intermediate Serotypes of Streptococcus pneumoniae Carried by Human Immunodeficiency Virus-Infected Adults and Healthy Children in Uganda. Microbial Drug Resistance 13:1, 21-28
CrossRef199
Michael T Fitch, Diederik van de Beek. (2007) Emergency diagnosis and treatment of adult meningitis. The Lancet Infectious Diseases 7:3, 191-200
CrossRef200
William P. Hausdorff, Rana Hajjeh, Abdulrahman Al-Mazrou, Atef Shibl, Montse Soriano-Gabarro. (2007) The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) Region—Current status and needs. Vaccine 25:11, 1935-1944
CrossRef201
Philippe Beutels, Nancy Thiry, Pierre Van Damme. (2007) Convincing or confusing?. Vaccine 25:8, 1355-1367
CrossRef202
D.R. Snydman. (2007) Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae. Yearbook of Medicine 2007, 93-94
CrossRef203
Guy W. Amsden. (2007) Regulatory disincentives for developing antibiotics for common indications?. Current Infectious Disease Reports 9:1, 29-34
CrossRef204
Ayman M Noreddin, Virginia Haynes. (2007) Use of Pharmacodynamic Principles to Optimise Dosage Regimens for Antibacterial Agents in the Elderly. Drugs & Aging 24:4, 275-292
CrossRef205
J.R. Maurer. (2007) Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae. Yearbook of Pulmonary Disease 2007, 200-202
CrossRef206
Françoise Van Bambeke, René R Reinert, Peter C Appelbaum, Paul M Tulkens, Willy E Peetermans. (2007) Multidrug-Resistant Streptococcus pneumoniae Infections. Drugs 67:16, 2355-2382
CrossRef207
Angel Vila-Córcoles. (2007) Advances in Pneumococcal Vaccines. Drugs & Aging 24:10, 791-800
CrossRef208
M. Morales‐Calderon, J. R. Stauffer, J. Davy Kirkpatrick, S. Carey, C. R. Gelino, D. Barrado y Navascues, L. Rebull, P. Lowrance, M. S. Marley, D. Charbonneau, B. M. Patten, S. T. Megeath, D. Buzasi. (2006) A Sensitive Search for Variability in Late L Dwarfs: The Quest for Weather. The Astrophysical Journal 653:2, 1454-1463
CrossRef209
Milan Čižman, Bojana Beović, Katja Seme, Metka Paragi, Iztok Štrumbelj, Manica Müller-Premru, Silva Čad-Pečar, Marko Pokorn. (2006) Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use. International Journal of Antimicrobial Agents 28:6, 537-542
CrossRef210
Juan J. Picazo, Carmen Betriu, Iciar Rodríguez-Avial, Ester Culebras, María Gómez, Fátima López. (2006) Vigilancia de resistencias a los antimicrobianos: estudio VIRA 2006. Enfermedades Infecciosas y Microbiología Clínica 24:10, 617-628
CrossRef211
Gregory B. Seymann. (2006) Community-acquired pneumonia: Defining quality care. Journal of Hospital Medicine 1:6, 344-353
CrossRef212
Helena Käyhty, Kari Auranen, Hanna Nohynek, Ron Dagan, Helena Mäkelä. (2006) Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Review of Vaccines 5:5, 651-667
CrossRef213
Cynthia G Whitney, Tamar Pilishvili, Monica M Farley, William Schaffner, Allen S Craig, Ruth Lynfield, Ann-Christine Nyquist, Kenneth A Gershman, Marietta Vazquez, Nancy M Bennett, Arthur Reingold, Ann Thomas, Mary P Glode, Elizabeth R Zell, James H Jorgensen, Bernard Beall, Anne Schuchat. (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. The Lancet 368:9546, 1495-1502
CrossRef214
Gary V Doern. (2006) Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance. Expert Review of Anti-infective Therapy 4:5, 821-835
CrossRef215
P. C. Hill, A. Akisanya, K. Sankareh, Y. B. Cheung, M. Saaka, G. Lahai, B. M. Greenwood, R. A. Adegbola. (2006) Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Villagers. Clinical Infectious Diseases 43:6, 673-679
CrossRef216
C. G. Grijalva, K. M. Edwards. (2006) Promises and Challenges of Pneumococcal Conjugate Vaccines for the Developing World. Clinical Infectious Diseases 43:6, 680-682
CrossRef217
Patrick Bättig, Lucy J. Hathaway, Sandra Hofer, Kathrin Mühlemann. (2006) Serotype-specific invasiveness and colonization prevalence in Streptococcus pneumoniae correlate with the lag phase during in vitro growth. Microbes and Infection 8:11, 2612-2617
CrossRef218
Andrew P. Steenhoff, Samir S. Shah, Adam J. Ratner, Sujata M. Patil, Karin L. McGowan. (2006) Reply to Robertson et al.. Clinical Infectious Diseases 43:4, 544-545
CrossRef219
Janelle L. Robertson, Mark Rasnake. (2006) Antibiotic Resistance after Licensure of Pneumococcal 7‐Valent Conjugate Vaccine. Clinical Infectious Diseases 43:4, 544-544
CrossRef220
Edward T Clarke, Robert S Heyderman. (2006) Current concepts in the treatment of bacterial meningitis beyond the neonatal period. Expert Review of Anti-infective Therapy 4:4, 663-674
CrossRef221
(2006) Potential Consequences of the Pneumococcal Conjugate Vaccine. New England Journal of Medicine 355:1, 95-96
Full Text222
Cynthia G. Whitney. (2006) Can Vaccines Control Resistance? The Example of Pneumococcal Conjugate Vaccine. Infectious Diseases in Clinical Practice 14:Supplement 4, S24-S30
CrossRef223
Torbjørn Wisløff, Tore G. Abrahamsen, Marianne A. Riise Bergsaker, Øistein Løvoll, Per Møller, Maren Kristine Pedersen, Ivar Sønbø Kristiansen. (2006) Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 24:29-30, 5690-5699
CrossRef224
Musher, Daniel M., . (2006) Pneumococcal Vaccine — Direct and Indirect (“Herd”) Effects. New England Journal of Medicine 354:14, 1522-1524
Full Text
- Letters
